123 related articles for article (PubMed ID: 38669521)
21. Predictive value of peripheral blood biomarkers in patients with non-small-cell lung cancer responding to anti-PD-1-based treatment.
Su S; Chen F; Lv X; Qi L; Ding Z; Ren W; Wei M; Liu Y; Yu L; Liu B; Wang L
Cancer Immunol Immunother; 2024 Jan; 73(1):12. PubMed ID: 38231411
[TBL] [Abstract][Full Text] [Related]
22. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
23. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis.
Wang C; Qiao W; Jiang Y; Zhu M; Shao J; Wang T; Liu D; Li W
J Cell Physiol; 2020 May; 235(5):4913-4927. PubMed ID: 31693178
[TBL] [Abstract][Full Text] [Related]
24. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
Zhang Z; Yuan F; Chen R; Li Y; Ma J; Yan X; Wang L; Zhang F; Tao H; Guo D; Huang Z; Zhang S; Li X; Zhi X; Ge X; Hu Y; Wang J
Front Immunol; 2020; 11():1173. PubMed ID: 32587591
[No Abstract] [Full Text] [Related]
25. Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non-Small Cell Lung Cancer.
Tsukita Y; Tozuka T; Kushiro K; Hosokawa S; Sumi T; Uematsu M; Honjo O; Yamaguchi O; Asao T; Sugisaka J; Saito G; Shiihara J; Morita R; Katakura S; Yasuda T; Hisakane K; Miyauchi E; Morita S; Kobayashi K; Asahina H
JAMA Oncol; 2024 Apr; 10(4):439-447. PubMed ID: 38451530
[TBL] [Abstract][Full Text] [Related]
26. Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
Xu Q; Zhang X; Huang M; Dai X; Gao J; Li S; Sheng L; Huang K; Wang J; Liu L
Front Immunol; 2021; 12():731546. PubMed ID: 34484242
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.
Wagner G; Stollenwerk HK; Klerings I; Pecherstorfer M; Gartlehner G; Singer J
Oncoimmunology; 2020 Jun; 9(1):1774314. PubMed ID: 32923134
[TBL] [Abstract][Full Text] [Related]
28. ICI plus chemotherapy prolonged survival over ICI alone in patients with previously treated advanced NSCLC.
Mao S; Zhou F; Liu Y; Yang S; Chen B; Xu J; Wu F; Li X; Zhao C; Wang W; Liu Q; Yu X; Jia K; Shao C; Zhou C; Gao G; Ren S
Cancer Immunol Immunother; 2022 Jan; 71(1):219-228. PubMed ID: 34097116
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study.
Kawachi H; Tamiya M; Taniguchi Y; Yokoyama T; Yokoe S; Oya Y; Imaji M; Okabe F; Kanazu M; Sakata Y; Uematsu S; Tanaka S; Arai D; Saito G; Kobe H; Miyauchi E; Okada A; Hara S; Kumagai T
JTO Clin Res Rep; 2022 Jul; 3(7):100355. PubMed ID: 35769388
[TBL] [Abstract][Full Text] [Related]
30. Analysis of the association between prior chemotherapy regimens and outcomes of subsequent anti-PD-(L)1 monotherapy in advanced non-small cell lung cancer.
Gao G; Jia K; Zhao S; Li X; Zhao C; Jiang T; Su C; Ren S; Zhou F; Zhou C
Transl Lung Cancer Res; 2019 Dec; 8(6):920-928. PubMed ID: 32010570
[TBL] [Abstract][Full Text] [Related]
31. Dynamic evaluation of blood immune cells predictive of response to immune checkpoint inhibitors in NSCLC by multicolor spectrum flow cytometry.
Ma W; Wei S; Long S; Tian EC; McLaughlin B; Jaimes M; Montoya DJ; Viswanath VR; Chien J; Zhang Q; Van Dyke JE; Chen S; Li T
Front Immunol; 2023; 14():1206631. PubMed ID: 37638022
[TBL] [Abstract][Full Text] [Related]
32. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
33. Bloodborne Cytokines for Predicting Clinical Benefits and Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated With Anti-Programmed Cell Death 1 Inhibitors.
Oyanagi J; Koh Y; Sato K; Teraoka S; Tokudome N; Hayata A; Akamatsu H; Ozawa Y; Nakanishi M; Ueda H; Yamamoto N
Clin Lung Cancer; 2021 Nov; 22(6):e833-e841. PubMed ID: 34049821
[TBL] [Abstract][Full Text] [Related]
34. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
[TBL] [Abstract][Full Text] [Related]
35. A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer.
Shao T; Zhao M; Liang L; Tang W
Front Immunol; 2022; 13():948597. PubMed ID: 36389713
[TBL] [Abstract][Full Text] [Related]
36. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
37. Potential predictive value of change in inflammatory cytokines levels subsequent to initiation of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer.
Lim JU; Yoon HK
Cytokine; 2021 Feb; 138():155363. PubMed ID: 33264749
[TBL] [Abstract][Full Text] [Related]
38. Serum cytokine analysis in a cohort of advanced non-small cell lung cancer treated with PD-1 inhibitors reveals predictive markers of CXCL12.
Xu Y; Ding L; Li H; Peng Z; Ding K; Huang Z; Zhou Z; Xie M; Yan J; Feng S; Fan Y
Front Immunol; 2023; 14():1194123. PubMed ID: 37359565
[TBL] [Abstract][Full Text] [Related]
39. A nomogram model based on peripheral blood lymphocyte subsets to assess the prognosis of non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Xu X; Wang D; Chen W; Li N; Suwinski R; Rossi A; Rosell R; Zhong J; Fan Y
Transl Lung Cancer Res; 2021 Dec; 10(12):4511-4525. PubMed ID: 35070757
[TBL] [Abstract][Full Text] [Related]
40. Plasmacytoid Dendritic Cell, Slan
Pettinella F; Lattanzi C; Donini M; Caveggion E; Marini O; Iannoto G; Costa S; Zenaro E; Fortunato TM; Gasperini S; Giani M; Belluomini L; Sposito M; Insolda J; Scaglione IM; Milella M; Adamo A; Poffe O; Bronte V; Dusi S; Cassatella MA; Ugel S; Pilotto S; Scapini P
Cancers (Basel); 2023 Nov; 15(21):. PubMed ID: 37958458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
